FAM20A

Across TCGA pan-cancer cohorts, FAM20A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM20A data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FAM20A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM20A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and BRCA are the cancer types where FAM20A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.166	0.786	<.001	33	view →
UCEC	DFS	Median	All	0.960	0.625	.020	20	view →
BRCA	OS	Median	All	0.159	0.579	.017	12	view →
SKCM	DFS	Median	All	0.297	0.734	<.001	11	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FAM20A–LIHC (OS)

Open the LIHC breakdown →